Is Sana Biotechnology, Inc. (SANA) a Buy, Sell, or Hold?
Sana Biotechnology, Inc.
NASDAQ:SANA
$3.57 USD
-$0.07 (-1.92%)
- Volume
- 2.02M
- Average Volume
- 3.82M
- Market Capitalization
- $993.5M
- P/E Ratio
- -3.84
- Dividend Yield
- 0.00%
- Price Target
- $7.00
- Year High
- $6.55
- Year Low
- $2.61
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.29
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Steven D. Harr |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | SANA |
| CUSIP | 799566104 |
| CIK | 0001770121 |
| Web | https://www.sana.com |
| Phone | 206 701 7914 |
| Currency | USD |
| Employees | 142 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.63 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.29 |
| Quick Ratio | 1.29 |
| Cash Ratio | 0.97 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -0.48 |
| Price / Cash Flow | -7.43 |
| Price / Book | 8.29 |
Price Target and Rating
| Average Stock Price Forecast | $7.00 |
| High Stock Price Forecast | $12.00 |
| Low Stock Price Forecast | $7.00 |
| Forecast Upside/Downside | -49.00% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 11 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.96 |
| Trailing P/E Ratio | -3.84 |
| PEG Ratio | 0.38 |
| P/E Growth | 0.38 |
| Net Income | $-244.17M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -161.87% |
| Return on Assets | -64.77% |
Financials Score
| AltmanZ Score | -6.39 |
| Piotroski Score | 1.00 |
| Working Capital | 25.42M |
| Total Assets | 373.59M |
| Ebit | -198.55M |
| Market Cap | 1.01B |
| Total Liabilities | 254.35M |
Poll Results
About Sana Biotechnology, Inc. (NASDAQ:SANA) Stock
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the comp ... any is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.
2026-07-13 08:00:00
Peer-Reviewed Letter to the Editor Describes Updated Long-Term Findings Consistent with Initial Trial Data Featured in NEJM Article Published in 2025
2026-07-01 09:00:00
SEATTLE, July 01, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced a symposium presentation highlighting clinical data from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana's hypoimmune platform (HIP) technology, into a patient with type 1 diabetes without any immunosuppression. The symposium will be held at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 taking place from September 28 - October 2, 2026 in Milan, Italy.
2026-06-10 02:22:10
Sana Biotechnology, Inc. (SANA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
2026-06-02 18:11:00
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Sana Biotechnology to Present at June 2026 Investor Conferences
2026-05-27 16:05:00
SEATTLE, May 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in June. The presentations will feature a business overview and update.
2026-05-15 09:00:00
SEATTLE , May 15, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has sold an aggregate of 21,607,878 shares of the company's common stock through its at-the-market (“ATM”) facility established through TD Securities (USA) LLC for net proceeds of approximately $69 million. The investment, including participation based on interest received from RA Capital Management, combined with the previously announced unrelated $25 million investment from the Mayo Clinic, brings the total capital raised since the end of the first quarter of 2026 to approximately $94 million and extends the company's expected cash runway to mid-2027.
2026-05-13 03:30:47
Sana Biotechnology, Inc. (SANA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
2026-05-12 16:05:00
SEATTLE, May 12, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the presentation of preclinical data demonstrating that a surrogate SG293, an in vivo CAR T cell therapy, achieved cell-specific delivery, robust and dose-dependent CAR T cell generation, and deep B cell depletion in non-human primates (NHPs) without the use of lymphodepleting chemotherapy. SG293 is a CD8-targeted fusosome that delivers the genetic material to make CD19-directed CAR T cells.
Frequently Asked Questions
-
What is the current Sana Biotechnology, Inc. (SANA) stock price?
-
Sana Biotechnology, Inc.(NASDAQ:SANA) stock price is $3.57 in the last trading session. During the trading session, SANA stock reached the peak price of $6.55 while $2.61 was the lowest point it dropped to. The percentage change in SANA stock occurred in the recent session was --1.92% while the dollar amount for the price change in SANA stock was -$-0.07.
-
SANA's industry and sector of operation?
-
The NASDAQ listed SANA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of SANA?
-
Brian D. Piper | Executive Vice President & Chief Financial Officer
Aaron Grossman | Executive VP, Chief Legal Officer & Corporate Secretary
John Gerecitano | Head of Oncology Research & Development
Snehal Patel | Senior Vice President & Chief Technical Officer
Dhavalkumar D. Patel | Executive Vice President & Chief Scientific Officer -
How many employees does SANA have?
-
Number of SANA employees currently stands at 142. SANA operates from 188 East Blaine Street, Seattle, WA 98102, US.
-
Link for SANA official website?
-
Official Website of SANA is: https://www.sana.com
-
How do I contact SANA?
-
SANA could be contacted at phone #206 701 7914 and can also be accessed through its website. SANA operates from 188 East Blaine Street, Seattle, WA 98102, US.
-
How many shares of SANA are traded daily?
-
The average number of SANA shares traded daily for last 3 months was 3.82M.
-
What is the market cap of SANA currently?
-
The market value of SANA currently stands at $993.5M with its latest stock price at $3.57